Guinea-Bissau
Tuberculosis profile
| High HIV burden |
Population  2012 1.7 million
Estimates of TB burden * 2012 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.49 (0.16–0.99) 29 (9.8–59)
Mortality (HIV+TB only) 0.56 (0.44–0.64) 34 (26–38)
Prevalence  (includes HIV+TB) 5.2 (2.5–8.9) 312 (148–537)
Incidence  (includes HIV+TB) 4 (3.3–4.8) 242 (200–289)
Incidence (HIV+TB only) 1.6 (1.3–1.9) 94 (77–112)
Case detection, all forms (%) 48 (40–58)    
TB case notifications 2012        
New cases   (%) Retreatment cases (%)
Smear-positive 1 324 (70) Relapse 51 (82)
Smear-negative 310 (16) Treatment after failure 6 (10)
Smear-unknown / not done 211 (11) Treatment after default 5 (8)
Extrapulmonary 43 (2) Other 0 (0)
Other 0 (0)      
Total new 1 888   Total retreatment 62  
           
Other (history unknown) 0        
Total new and relapse 1 939   Total cases notified 1 950  
New cases Smear-positive Smear-negative/ unknown/
not done
Extrapulmonary
M:F ratio 1.6 1.3 1.7
Age < 15 14 70 8
Laboratories 2012
Smear (per 100 000 population) 1.3
Culture (per 5 million population) 3.0
Drug susceptibility testing (per 5 million population) 0
Is second-line drug susceptibility testing available? Yes, outside
country
Treatment success rate 2011 (%)        
New smear-positive and/or culture-positive 73   Is rifampicin used
throughout treatment for
new patients?
Yes
New smear-negative/extrapulmonary 61  
Retreatment 68  
TB/HIV 2012 Number (%)
TB patients with known HIV status 1 322 (68)
HIV-positive TB patients 517 (39)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 0 (0)
HIV-positive TB patients on antiretroviral therapy (ART) 0 (0)
HIV-positive people screened for TB    
HIV-positive people provided with IPT 0  
Estimates of MDR-TB burden 2012*   New   Retreatment
% of TB cases with MDR-TB 1.8 (0.1–3.4) 19 (7.4–31)
MDR-TB cases among notified pulmonary
TB cases
33 (2–63) 12 (5–19)
Reported cases of MDR-TB 2012 New Retreatment Total
Cases tested for MDR-TB      
Laboratory-confirmed MDR-TB cases     6
Patients started on MDR-TB treatment     9
Financing TB control 2013
National TB programme budget (US$ millions)  
% Funded domestically  
% Funded internationally  
% Unfunded  
***
(Rate per 100 000 population per year)
Mortality graph
___ Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
___ Prevalence

(Rate per 100 000 population per year)
Incidence graph
__ Notifications Incidence
___
___ Incidence (HIV+TB only)

Treatment success rate (%)
tx success graph
__ New smear-positive and/or culture-positive
__ New smear-negative/extrapulmonary __
Retreatment

(Number of patients)
CPT ART graph
__ HIV-positive TB patients
__ on CPT __ on ART

Total budget (US$ millions)
Budget funding Graph
__ Funded domestically __ Funded internationally
__ Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 * Ranges represent uncertainty intervals Generated: 2014-04-17 Data: www.who.int/tb/data